AstraZeneca has expanded its agreement with US group Myriad Genetics to identify women with advanced ovarian cancer most likely to benefit from its medicines. More: AZ deepens ties with Myriad on Lynparza companion test Source: News
read moreAllergan has unveiled plans to trim more than 1,000 jobs from its workforce in a bid to reduce costs and prepare for increased generic competition this year. More: Allergan announces job cull to cut costs Source: News
read moreThe Care Quality Commission is to get new powers to award quality ratings to wider range of healthcare services, including websites for medical advice and prescriptions from GPs online. More: CQC to rate health websites and non-NHS services Source: News
read moreApotex has run into lots of regulatory issues with the FDA over the years, but now it is regulators in the U.K. that are expressing concern. And it comes at an uncertain time for Canada’s largest drugmaker after founder and
read moreBack in November, as investors were digesting the news that Allergan’s eye blockbuster Restasis could face early generic competition, CEO Brent Saunders promised investors that cost cuts were coming “rapidly.” Just over two months later, they’re here. More: Allergan chops
read moreWhen Impax Laboratories CEO Paul Bisaro started cutting costs at the struggling drug company, one move involved the “difficult decision” to let go of its manufacturing site in Taiwan, even though issues at the plant had contributed to the company’s
read more© 1994 - 2026 B.M. Pharmaceuticals